GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of reading SURMOUNT threads from 2024 and half of it aged badly — 13 comments in the full submission. View in context.
77
c/trialwatch·submitted 1 months ago by u/yara_mensah

reading SURMOUNT threads from 2024 and half of it aged badly

Press Releasebranch of 6 comments

reading SURMOUNT threads from 2024 and half of it aged badly, and I am aware this is a minority view on this board. Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group. Relative risk reduction without the baseline rate is…

Read the full submission and all 13 comments →

This branch

6 comments, started 1 months ago
u/tomas_kimani8 points·1 months ago·edited

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/hazard_ratio_halstats2 points·1 months ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/yara_mensahOP1 point·1 months ago

Do you have the publication or the press release?

replysharereportpermalink
u/heart_rate_bump1 point·1 months ago

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

replysharereportpermalink
u/rulebook_rachaelmod · c/meta1 point·1 months ago

open-label extensions are not the same evidence as the randomised phase

replysharereportpermalink
u/emil_agyeman1 point·1 months ago

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →